Shares of DaVita Inc. (NYSE:DVA – Get Free Report) have earned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $199.1667.
DVA has been the topic of several research analyst reports. Barclays boosted their price target on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Truist Financial boosted their price target on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and boosted their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Finally, Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th.
DaVita Stock Performance
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the firm posted $2.00 earnings per share. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts expect that DaVita will post 15.07 EPS for the current fiscal year.
Insider Activity
In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Kesler Norman & Wride LLC increased its stake in DaVita by 0.8% in the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after acquiring an additional 55 shares during the period. Gen Wealth Partners Inc increased its stake in DaVita by 10.0% in the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after acquiring an additional 80 shares during the period. NewEdge Advisors LLC increased its stake in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Orion Porfolio Solutions LLC increased its stake in DaVita by 4.4% in the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after acquiring an additional 99 shares during the period. Finally, Root Financial Partners LLC increased its stake in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the period. Institutional investors own 90.12% of the company’s stock.
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Articles
- Five stocks we like better than DaVita
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
